ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -133.2 Million EUR | -132.59% |
| 2022 | -53.31 Million EUR | -33.2% |
| 2021 | -42.37 Million EUR | -10.94% |
| 2020 | -38.19 Million EUR | -14.73% |
| 2019 | -33.22 Million EUR | -75.24% |
| 2018 | -19.22 Million EUR | -36.21% |
| 2017 | -13.98 Million EUR | 21.9% |
| 2016 | -17.86 Million EUR | 1.07% |
| 2015 | -18.11 Million EUR | -107.57% |
| 2014 | -5 Million EUR | -17.95% |
| 2013 | -7.37 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -39.91 Million EUR | 0.0% |
| 2024 Q1 | -39.91 Million EUR | 11.35% |
| 2023 Q3 | -45.02 Million EUR | -14.84% |
| 2023 FY | - EUR | -132.59% |
| 2023 Q1 | -18.6 Million EUR | 51.03% |
| 2023 Q2 | -39.2 Million EUR | -110.76% |
| 2023 Q4 | -45.02 Million EUR | 0.0% |
| 2022 Q3 | -18.07 Million EUR | 2.76% |
| 2022 FY | - EUR | -33.2% |
| 2022 Q4 | -37.98 Million EUR | -110.2% |
| 2022 Q2 | -18.58 Million EUR | -147.48% |
| 2022 Q1 | -7.51 Million EUR | 70.62% |
| 2021 Q4 | -25.56 Million EUR | -126.47% |
| 2021 Q1 | -13.24 Million EUR | 43.28% |
| 2021 Q2 | -26.5 Million EUR | -100.08% |
| 2021 FY | - EUR | -10.94% |
| 2021 Q3 | -11.28 Million EUR | 57.4% |
| 2020 Q4 | -23.35 Million EUR | -99.99% |
| 2020 Q2 | -16.17 Million EUR | -100.0% |
| 2020 Q3 | -11.67 Million EUR | 27.84% |
| 2020 Q1 | -8.08 Million EUR | 49.54% |
| 2020 FY | - EUR | -14.73% |
| 2019 Q3 | -8.01 Million EUR | 53.3% |
| 2019 Q4 | -16.03 Million EUR | -100.04% |
| 2019 FY | - EUR | -75.24% |
| 2019 Q1 | -8.59 Million EUR | -63.37% |
| 2019 Q2 | -17.16 Million EUR | -99.73% |
| 2018 FY | - EUR | -36.21% |
| 2018 Q3 | -5.25 Million EUR | -23.48% |
| 2018 Q2 | -4.25 Million EUR | 0.0% |
| 2018 Q1 | -4.25 Million EUR | -27.24% |
| 2018 Q4 | -5.25 Million EUR | 0.0% |
| 2017 Q1 | -3.68 Million EUR | 2.91% |
| 2017 Q2 | -3.68 Million EUR | 0.0% |
| 2017 Q3 | -3.34 Million EUR | 9.06% |
| 2017 Q4 | -3.34 Million EUR | 0.0% |
| 2017 FY | - EUR | 21.9% |
| 2016 Q2 | -5.29 Million EUR | 0.0% |
| 2016 FY | - EUR | 1.07% |
| 2016 Q3 | -3.79 Million EUR | 28.37% |
| 2016 Q1 | -5.29 Million EUR | -4.65% |
| 2016 Q4 | -3.79 Million EUR | 0.0% |
| 2015 Q1 | -4.03 Million EUR | -88.88% |
| 2015 Q2 | -4.03 Million EUR | 0.0% |
| 2015 Q3 | -5.05 Million EUR | -25.37% |
| 2015 Q4 | -5.05 Million EUR | 0.0% |
| 2015 FY | - EUR | -107.57% |
| 2014 FY | - EUR | -17.95% |
| 2014 Q4 | -2.13 Million EUR | -1.36% |
| 2014 Q2 | 105.5 Thousand EUR | 0.0% |
| 2014 Q1 | 105.5 Thousand EUR | 0.0% |
| 2014 Q3 | -2.1 Million EUR | -2097.63% |
| 2013 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -9402.514% |
| CSL Limited | 4.78 Billion USD | 102.782% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -87.52% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -2146.737% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -55600.188% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -666.88% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 241.652% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -8572.054% |
| Mesoblast Limited | -62.38 Million USD | -113.508% |
| Marizyme, Inc. | -34.28 Million USD | -288.569% |
| Genus plc | 73.7 Million USD | 280.742% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1914.772% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -3655.486% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -1418.548% |
| ContraFect Corporation | -64.99 Million USD | -104.937% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -2843.024% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | -274.984% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -5632.243% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -25613.354% |
| Accustem Sciences Inc. | -3.74 Million USD | -3455.582% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -176.208% |
| EV Biologics, Inc. | -1.26 Million USD | -10412.48% |
| Q BioMed Inc. | -617.62 Thousand USD | -21467.513% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 3829.199% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -5730.932% |
| Biomind Labs Inc. | -1.03 Million USD | -12775.852% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1760.102% |
| Skye Bioscience, Inc. | -13.54 Million USD | -883.255% |
| SQZ Biotechnologies Company | -64.14 Million USD | -107.678% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -532728.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -3329.352% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -4937.233% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -739.377% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -20963.526% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 1448.658% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -8855.622% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -5224.102% |
| GB Sciences, Inc. | -1.41 Million USD | -9281.534% |
| Alpha Cognition Inc. | -9.7 Million USD | -1272.476% |
| argenx SE | -216.02 Million USD | 38.337% |
| HST Global, Inc. | -5303.00 USD | -2511817.782% |
| Halberd Corporation | -74.27 Thousand USD | -179233.324% |
| Enzolytics Inc. | -2.12 Million USD | -6177.341% |
| Resverlogix Corp. | -11.74 Million USD | -1034.449% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -4248.884% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -140.711% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -236.069% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 11045.522% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -4505.532% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1604.518% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1981167.817% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -8786.948% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 35261.438% |
| AVAX Technologies, Inc. | -6.11 Million USD | -2079.205% |
| ONE Bio Corp. | 13.61 Million USD | 1078.525% |
| Zenith Capital Corp. | -8.6 Million USD | -1447.839% |
| Genscript Biotech Corporation | -248.71 Million USD | 46.443% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -764534.636% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -5344.885% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -75575.321% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -6834.574% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -6375.79% |
| Agentix Corp. | -1.37 Million USD | -9610.692% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -4975.749% |
| Helix BioMedix, Inc. | -1.04 Million USD | -12631.097% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -7511.833% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1663.48% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -73459.264% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 32409.603% |
| Cell Source, Inc. | -4.27 Million USD | -3017.758% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -36174.342% |
| Regen BioPharma, Inc. | 1.46 Million USD | 9186.698% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -14117.103% |
| NovAccess Global Inc. | -1.03 Million USD | -12772.766% |
| Affymax, Inc. | -14.29 Million USD | -831.843% |
| Itoco Inc. | -1.86 Million USD | -7027.199% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -34989.563% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -11836.111% |
| CytoDyn Inc. | -18.02 Million USD | -638.849% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -168454.581% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -1089171.404% |
| Qrons Inc. | -40.08 Thousand USD | -332244.502% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -27327.02% |
| SYBLEU INC | -141.57 Thousand USD | -93992.01% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 25355.72% |
| Rebus Holdings, Inc. | -951 Thousand USD | -13907.045% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -12442.914% |
| Mobile Lads Corp. | -2.24 Million USD | -5843.666% |
| International Stem Cell Corporation | 202 Thousand USD | 66044.059% |
| Bioxytran, Inc. | -3.82 Million USD | -3386.96% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -252952.812% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -5310.669% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -271.371% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -295915.556% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -4765.121% |
| Neutra Corp. | -181.24 Thousand USD | -73394.734% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -560.782% |
| PureTech Health plc | -11.62 Million USD | -1045.67% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -560.827% |
| IXICO plc | -707 Thousand USD | -18741.16% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1633.338% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -175.528% |
| CSL Limited | 4.73 Billion USD | 102.814% |
| Cellectis S.A. | -92.63 Million USD | -43.796% |